Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Pharmaceutical Drug Export from Russia (September and Q1 – Q3 2020)

Monday, December 7, 2020

Between January and September 2020, Russia exported RUB 40.2 bln worth of ready-made pharmaceutical drugs (customs duties included), which is virtually comparable of the total export volume in 2018. The dynamics in monetary terms (rubles) are as high as +23.3%. The export volume in physical terms amounts to 0.83 bln units, with the dynamics of +27.5%.

The EEU countries account for 38.1% (against 38.5% in Q1 – Q3 2019) of the export of ready-made drugs in monetary terms, amounting to RUB 15.3 bln. This time, the dynamics in monetary terms are lower than those of the drug exports to other countries (+22% against +24%). Among the EEU countries, Kazakhstan both accounted for the highest export volume (RUB 7.5 bln) and had the best dynamics in monetary terms (+48%).

Kazakhstan is followed by Belarus, which has the second best export volume (RUB 6 bln), but the worst dynamics (+2% in monetary terms). The dynamics of the export to Kyrgyzstan and Armenia are nearly identical, +13% and +12%, respectively. However, the export volume of the two countries totals only RUB 1.8 bln.

During the first 9 months of 2020, Russia was exporting pharmaceutical drugs to 88 countries, excluding the EEU. Ukraine (mostly DPR and LPR) and Uzbekistan account for the highest volume, with the dynamics of +27% and +25% in monetary terms, respectively. Lebanon has the best dynamics; the exports has grown by 536 times, but the export volume amounts to only RUB 719 thousand. Two Russian manufacturers were exporting three trademarks to Lebanon; AVVA Pharmaceuticals accounts for the largest volume with Lactofiltrum and Filtrum, and Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences exported Yellow Fever Vaccine.

The exports to Macedonia has increased by 74 times. Between January and September 2020, Russia was exporting 5 trademarks there. Sotex accounts for the highest volume with BloccoC (Bupivacaine) and Octretex (Octreotide), then comes Drugs Technology (R-Pharm Group) with its Coronavir (Favipiravir). Drugs based on Favipiravir have become a significant part of the export, with the total volume of RUB 440 mln (excluding the EEU). Turkmenistan, Bolivia and Uzbekistan account for the largest volumes.

This year, Russian manufacturers have also started exporting to four new directions, out of which the Dominican Republic accounts for the highest volume (RUB 2.2 mln). The only drugs exported there was Rituximab by Biocad.

Dynamics and volume of ready-made drug export from Russia (EEU countries included), bln RUB (prices include customs duties) (2015 – 2019, Q1 – Q3 2020)